Physiomics Plc

Physiomics Plc

Physiomics Plc

Overview
Date Founded

2001

Headquarters

The Magdalen Centre,Robert Robinson Avenue,Oxford Science Park,Oxford, Oxfordshire OX4 4GA

Type of Company

Public

Employees (Worldwide)

2

Industries

Medical Support Services
Engineering, Construction & Architecture
Medical Products & Equipment

Company Description

Physiomics Plc engages in the provision of outsourced systems and computational biology services to pharmaceutical companies. Its services include target validation, mechanism of action studies, lead selection, clinical PK or PD, EasyAP or cardiac toxicity service, virtual tumour preclinical, and virtual tumour clinical. The company was founded by David A. Fell and Peter Hoskins in May 2001 and is headquartered in Oxford, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at Physiomics Plc? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Executive Director

Chief Operating Officer & Executive Director

Finance Director & Secretary

Company Secretary

Administration Manager

Board of Directors

Former Director, Research & Development at Johnson & Johnson

Chief Operating Officer & Executive Director at Physiomics Plc

Chief Executive Officer & Executive Director at Physiomics Plc

Secretary at Nuformix Plc

Paths to Physiomics Plc
Potential Connections via
Relationship Science
You
Physiomics Plc
Recent Transactions
Details Hidden

Physiomics Plc issued GBP Ordinary Shares

Details Hidden

Physiomics Plc issued GBP Ordinary Shares

Details Hidden

Physiomics Plc issued GBP Ordinary Shares

Transaction Advisors
Broker

Advised onPhysiomics Plc issued GBP Ordinary Shares

Investment Advisor

Advised onPhysiomics Plc issued GBP Ordinary Shares

Auditor

Advised onPhysiomics Plc issued GBP Ordinary Shares

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Key Stats and Financials As of 2020
Market Capitalization
$10.5M
Total Enterprise Value
$5.04M
Earnings Per Share
$0
EBITDAMargin
-20.98%
Enterprise Value / Sales
5.1x
TEVNet Income
-63.27x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
53.8%
Revenue
$987K
Net Profit
$-74.1K
EBITDA
$-207K
Total Debt
$0
Total Equity
$1.62M
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Physiomics Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Physiomics Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and Physiomics Plc.